IGF-1 promotes multiple myeloma progression through PI3K/Akt-mediated epithelial-mesenchymal transition

IGF-1 通过 PI3K/Akt 介导的上皮-间质转化促进多发性骨髓瘤进展

阅读:10
作者:Yue Peng, Fangmei Li, Peihua Zhang, Xiaman Wang, Ying Shen, Yuandong Feng, Yachun Jia, Ru Zhang, Jinsong Hu, Aili He

Aims

To investigate the role and mechanism of insulin-like growth factor 1(IGF-1)-mediated EMT on multiple myeloma (MM) growth and metastasis. Materials and

Methods

The expression data from GEO datasets were utilized to explore the expression levels of IGF-1 and epithelial-mesenchymal transition (EMT) markers in MM. Western blotting and flow cytometry analysis were performed to detect the protein levels of EMT markers as well as key components of the PI3K/Akt pathway. Cell proliferation ability was assessed using colony formation assay and EdU incorporation assays. Transwell migration and invasion assays were performed to assess cell metastasis properties. Vimentin was knocked down by using electro-transfection with small interfering RNA (siRNA) to detect the effect of IGF-1-mediated EMT on MM cell growth and metastasis. Key findings: First of all, the analysis of GEO database revealed that IGF-1 was excessively expressed and closely correlated with the expression of the EMT markers in MM patients. Furthermore, we demonstrated that IGF-1 enhanced the acquisition of mesenchymal features in a time-dependent manner. Additionally, in vitro studies revealed that IGF-1-mediated mesenchymal phenotype promoted MM migration, invasion and colony formation. Finally, the mechanism study showed PI3K/Akt signaling pathway was involved in the IGF-1-induced EMT in MM cells. Significance: IGF-1-induced mesenchymal phenotype contributed to MM progression via the PI3K/Akt pathway regulation.

Significance

IGF-1-induced mesenchymal phenotype contributed to MM progression via the PI3K/Akt pathway regulation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。